Afferent Corporation aims to establish a leadership position in the emerging field of neurotherapeutic devices by pioneering the development of a new class of noninvasive and minimally invasive medical devices to treat chronic neurological dysfunction.

Founded in January 2000 by Jason D. Harry, Ph.D., Afferent is commercializing a breakthrough technology developed initially by James J. Collins, Ph.D., of Boston University. The technology directly enhances the function of sensory cells. This ongoing boost of information-rich sensory information constitutes a unique pathway for accessing the central nervous system (brain and spinal cord), and provides a means of treating a wide range of neurological problems.